company background image
XLS

Xlife Sciences SWX:XLS Stock Report

Last Price

CHF31.00

Market Cap

CHF163.8m

7D

0.6%

1Y

n/a

Updated

27 Nov, 2022

Data

Company Financials
XLS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health2/6
Dividends0/6

XLS Stock Overview

Xlife Sciences AG focuses on the development and commercialization of technologies in the life sciences industry.

Xlife Sciences AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Xlife Sciences
Historical stock prices
Current Share PriceCHF31.00
52 Week HighCHF52.00
52 Week LowCHF23.30
Beta0
1 Month Change3.33%
3 Month Change-11.43%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-32.97%

Recent News & Updates

Recent updates

Shareholder Returns

XLSCH Life SciencesCH Market
7D0.6%3.0%1.2%
1Yn/a-33.0%-11.8%

Return vs Industry: Insufficient data to determine how XLS performed against the Swiss Life Sciences industry.

Return vs Market: Insufficient data to determine how XLS performed against the Swiss Market.

Price Volatility

Is XLS's price volatile compared to industry and market?
XLS volatility
XLS Average Weekly Movement6.9%
Life Sciences Industry Average Movement6.2%
Market Average Movement4.5%
10% most volatile stocks in CH Market8.1%
10% least volatile stocks in CH Market2.3%

Stable Share Price: XLS is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: XLS's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Swiss stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a13Oliver Baumannhttps://www.xlifesciences.ch

Xlife Sciences AG focuses on the development and commercialization of technologies in the life sciences industry. The company’s project consists of technology platforms that focuses to identify new therapeutic approaches and biomarkers for common diseases based on human genetic data; focuses on functional screening of antibodies by microfluidics-based technologies; and provides services for drug development. It also develops mono-and bispecific anti-tumor antibodies for the treatment of life-threatening diseases, with a focus on orphan hematopoietic malignancies; researches, develops, and manufactures chemical and active pharmaceutical ingredients for human and veterinary medicine; and develops new methods for the early identification of kidney diseases.

Xlife Sciences AG Fundamentals Summary

How do Xlife Sciences's earnings and revenue compare to its market cap?
XLS fundamental statistics
Market CapCHF163.80m
Earnings (TTM)CHF48.92m
Revenue (TTM)CHF863.90k

3.3x

P/E Ratio

189.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XLS income statement (TTM)
RevenueCHF863.90k
Cost of RevenueCHF528.78k
Gross ProfitCHF335.12k
Other Expenses-CHF48.58m
EarningsCHF48.92m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)9.26
Gross Margin38.79%
Net Profit Margin5,662.55%
Debt/Equity Ratio19.1%

How did XLS perform over the long term?

See historical performance and comparison